Novel Monoclonal Antibodies to Treat Carbapenem-Resistant Klebsiella Pneumoniae Infections


Carbapenem-resistant K.pneumonia (CR-Kp) strains are a major threat worldwide due to the difficult to treat. Lack of new antibiotics in pipeline and the emergence of resistance to the last-resource antibiotics has resulted in an urgent need to develop novel treatment strategy. Such a treatment strategy would ideally be:1. not susceptible to resistance development and,2. specific to pathogenic organism without affecting microbiome.


Researchers at Stony Brook University have developed an antibody based approach overcoming the problems associated with the use of antibiotics. The mABs bind to all clade 2 capsular polysaccharides of the carbapenem resistant ST258 Klebsiella clonal group. These mabs promote opsonophagocytic activity and bacterial killing in culture and were demonstrated to promote lung clearance and reduce dissemination of bacteria in infected mice. These mABs target 50-80% of strains of ST258 CR-Kp, the most abundant clone in the US. Clade 2 strains are associated with higher mortality (Figure 1.).Further Details: Diago-Navarro et al. mBio 9 (2), e00091-18. 2018


-Highly specific to pathogen, leaves microbiome unaltered-Less likely to promote drug resistance-Protective against pulmonary infection model-Long serum half life of mABs results in reduced dosing frequency


- Infectious diseases - Therapeutics - Diagnostics

Patent Status


Stage Of Development


Licensing Potential


Licensing Status


Additional Info Please note, header image is purely illustrative. Source: Николай Смолянкин, Wikimedia Commons, CC BY-SA 4.0.
Patent Information:
Case ID: R050-8930
For Information, Contact:
Sean Boykevisch
State University of New York at Stony Brook
Bettina Fries
Elizabet Diago Navarro